Elevation Operating Income from 2010 to 2024
| ELEV Stock | USD 0.61 0.03 5.17% |
Operating Income | First Reported 2010-12-31 | Previous Quarter -45.4 M | Current Value -47.7 M | Quarterly Volatility 25.5 M |
Check Elevation Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elevation Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37 K, Interest Expense of 4.4 M or Selling General Administrative of 9.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.35. Elevation financial statements analysis is a perfect complement when working with Elevation Oncology Valuation or Volatility modules.
Elevation | Operating Income |
Latest Elevation Oncology's Operating Income Growth Pattern
Below is the plot of the Operating Income of Elevation Oncology over the last few years. Operating Income is the amount of profit realized from Elevation Oncology operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Elevation Oncology is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Elevation Oncology's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Elevation Oncology's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Elevation Operating Income Regression Statistics
| Arithmetic Mean | (19,723,550) | |
| Coefficient Of Variation | (129.39) | |
| Mean Deviation | 18,781,740 | |
| Median | (5,882,000) | |
| Standard Deviation | 25,520,029 | |
| Sample Variance | 651.3T | |
| Range | 88.7M | |
| R-Value | (0.70) | |
| Mean Square Error | 361.4T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (3,972,849) | |
| Total Sum of Squares | 9117.8T |
Elevation Operating Income History
Other Fundumenentals of Elevation Oncology
Elevation Oncology Operating Income component correlations
Click cells to compare fundamentals
About Elevation Oncology Financial Statements
Elevation Oncology investors use historical fundamental indicators, such as Elevation Oncology's Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Elevation Oncology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Income | -45.4 M | -47.7 M | |
| Non Operating Income Net Other | -455.4 K | -478.2 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.